Many ovarian tumors respond to initial drug therapy, but become refractory to drug treatment upon recurrence. Therefore, defining the mechanisms of drug resistance is important for existing and new cancer therapies. Alternative mRNA splicing affects 74% of the human genome. Alterations in alternative mRNA splicing factor expression occur in cancer and can strongly influence apoptotic responses. Over-expression of the splicing factor SPF45 in ovarian cancer cells results in a tamoxifen sensitive drug-resistant phenotype. The mechanism of SPF45-mediated drug resistance is unknown. Numerous chemotherapeutic agents and cellular stimuli induce activation the mitogen-activated protein kinases (MAP kinases) ERK, JNK and p38, all of which are associated with modulating cell survival responses through phosphorylation of their protein substrates. Currently, Sam68 is the only known splicing factor affected by MAP kinase phosphorylation. We have identified SPF45 as a novel substrate of all three MAP kinases and identified two phosphorylation sites on SPF45. We generated phospho-specific antibodies and have shown SPF45 phosphorylation in human ascites and in cell lines in response to chemotherapeutic drugs, oxidative stress, phorbol esters and UV irradiation. Most importantly, phosphorylation of SPF45 on Ser222 by MAP kinases increases its alternative splicing activity. These data strongly demonstrate a direct link between MAP kinases, SPF45 phosphorylation, alternative splicing activity and drug resistance. The overall objective of this application is to define the mechanism by which SPF45 mediates drug resistance and how resistance is regulated by MAP kinase phosphorylation of SPF45. These studies will enable the identification of novel targets for therapeutic intervention to combat drug resistance in SPF45 over-expressing tumors. We hypothesize that MAP kinase phosphorylation of SPF45 in response to chemotherapeutic agents enhances the drug resistant phenotype by stimulating SPF45 alternative splicing activity. We will test this hypothesis through the following Specific Aims:
Specific Aim 1. Generate phospho-specific antibodies to SPF45. Identify the changes in MAP kinase- specific SPF45 phosphorylation patterns in response to chemotherapeutic agents and identify the kinase(s) involved.
Specific Aim 2. Determine the effect of MAP kinase phosphorylation on SPF45 splicing activity using the ?fas minigene assay. Identify novel splicing targets of SPF45 by exon array analysis and identify the mechanism by which these targets contribute to SPF45-mediated drug resistance.
Specific Aim 3. Elucidate the role of SPF45 and its phosphorylation in the response to chemotherapeutic agent treatment in pre-neoplastic and neoplastic ovarian cell lines, tumors in nude mice and in malignant human ascites. Define the role o estrogen receptors in SPF45-mediated drug resistance.

Public Health Relevance

ovarian tumors often develop resistance to chemotherapeutics, but the mechanisms are poorly understood. We hypothesize that this phenomenon is regulated in part by the ability of an intracellular signaling pathway that is often hyper-activated in cancer cells to chemically modify a protein with a known role in drug resistance. Elucidation of this synergistic mechanism of drug resistance would provide important information for treating drug-resistant ovarian cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA131200-04
Application #
8211093
Study Section
Basic Mechanisms of Cancer Therapeutics Study Section (BMCT)
Program Officer
Forry, Suzanne L
Project Start
2009-05-01
Project End
2014-01-31
Budget Start
2012-02-01
Budget End
2013-01-31
Support Year
4
Fiscal Year
2012
Total Cost
$296,116
Indirect Cost
$94,841
Name
Medical University of South Carolina
Department
Pharmacology
Type
Schools of Medicine
DUNS #
183710748
City
Charleston
State
SC
Country
United States
Zip Code
29425
Bradley, Amber; Zheng, Hui; Ziebarth, Angela et al. (2014) EDD enhances cell survival and cisplatin resistance and is a therapeutic target for epithelial ovarian cancer. Carcinogenesis 35:1100-9
Ali, Mourad W; Cacan, Ercan; Liu, Yuying et al. (2013) Transcriptional suppression, DNA methylation, and histone deacetylation of the regulator of G-protein signaling 10 (RGS10) gene in ovarian cancer cells. PLoS One 8:e60185
Liu, Yuying; Conaway, LaShardai; Rutherford Bethard, Jennifer et al. (2013) Phosphorylation of the alternative mRNA splicing factor 45 (SPF45) by Clk1 regulates its splice site utilization, cell migration and invasion. Nucleic Acids Res 41:4949-62
Eblen, Scott T (2012) Regulation of chemoresistance via alternative messenger RNA splicing. Biochem Pharmacol 83:1063-72
Gault, Christopher R; Eblen, Scott T; Neumann, Carola A et al. (2012) Oncogenic K-Ras regulates bioactive sphingolipids in a sphingosine kinase 1-dependent manner. J Biol Chem 287:31794-803
Al-Ayoubi, Adnan M; Zheng, Hui; Liu, Yuying et al. (2012) Mitogen-activated protein kinase phosphorylation of splicing factor 45 (SPF45) regulates SPF45 alternative splicing site utilization, proliferation, and cell adhesion. Mol Cell Biol 32:2880-93